Video-on-Demand Library

This content is restricted to members of PSI. If you are already a member please login. To join PSI or to see all the benefits of membership click here.

04 May 2021

Khadija Rantell (MHRA), Jiawei Wei (Novartis), Bohdana Ratitch (Bayer)

Incomplete datasets due to missing data is an issue that has been, and will be, around for a long time. At this meeting we will present the evolution of missing data approaches, looking at how they have been handled in the past, the current established missing data approaches and the impact of the new ICH E9 R1 addendum on the handling of missing data, focussing in particular on the treatment policy estimand.

Khadija Rantell (MHRA) History of missing data in regulatory settings. Jiawei Wei (Novartis) On the role of hypothetical estimand in clinical trials and its estimation. Bohdana Ratitch (Bayer) Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic. Panel discussion (led by Khadija Rantell) other panel members Daniel Bratton, David Wright, James Bell, Michael O’Kelly, Bohdana Ratitch.

Key Timings
04:30 
- Introduction & Welcome
06:18 - Khadija Rantell
44:30 - Jiawei Wei
1:38:00 - Bohdana Ratitch
2:23:50 - Panel Q&A

Part of Collection(s)

Topic(s)

Upcoming Events

Latest Jobs